Stealth Bio's neuromuscular disorder drug fails trial; shares plummet

Stealth BioTherapeutics Corp's shares crashed on Friday after its lead neuromuscular disorder drug candidate failed to help patients walk better and reduce fatigue, a major setback to the company's wide mitochondrial diseases pipeline.

from Reuters: Health News https://ift.tt/34D6Ws5